Skip to main content

Table 2 MDGs dysregulate expression levels of chromatin regulators

From: A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes

MDGs

|Ti|

N1 (# of dysregulated genes)

N2 (# of

dysregulated

genes in list A)

Enrichment PvalueA

N3 (# of

dysregulated

genes in list B)

Enrichment PvalueB

Genes in list B that are dysregulateda

Genes in list B that are

differentially methylatedb

TP53

8

233

19

0.00056

5

3.2e-06

CBX7 RAD54L TTF2 KDM1A SUV39H2

 

PTEN

3

1,534

81

0.00012

9

9.1e-06

DNMT1 DNMT3A SETBP1 PRDM5 CBX7 RAD54L EZH2 PCNA HDAC1

DNMT3A PRDM5 HDAC1

RB1

2

1,447

83

5.2e-06

4

0.056

DNMT1 EYA4 EZH2 PCNA

PCNA

NF1

2

766

36

0.044

0

1

  

CTNNB1

2

5,515

207

0.12

12

0.0033

DNMT1 SETBP1 PRDM2 PRDM5 CBX7 KAT2B RAD54L WHSC1 EZH2 UHRF1 TDG TET3

PRDM2 CBX7

HRAS

2

1,137

63

2.0e-04

3

0.11

PRDM2 RAD54L HDAC1

PRDM2

BRAF

2

3,128

133

0.008

8

0.0091

DNMT1 DNMT3A DNMT3B KAT2B WHSC1 EZH2 UHRF1 KDM1A

DNMT3A UHRF1

IDH1

2

3,560

208

2.8e-15

2

0.9

SUV39H2 TET3

 

NRAS

2

1,609

87

2.8e-05

1

0.82

HDAC1

 

RNF43

2

3,212

157

4.4e-06

8

0.011

DNMT3A DNMT3B PRDM2 RAD54L WHSC1 UHRF1 HDAC1 TET3

DNMT3A DNMT3B PRDM2 WHSC1

ZBTB20

2

1,563

78

0.00088

6

0.0039

DNMT3A RAD54L WHSC1 UHRF1 TTF2 HDAC1

DNMT3A WHSC1 UHRF11

CDH1

2

2,792

136

2.7e-05

14

3.3e-08

DNMT3B SETBP1 PRDM2 CBX7 DUSP1 RAD54L WHSC1 EZH2 PCNA KDM1A SUV39H2 HDAC1 TDG TET3

PRDM2 CBX7 WHSC1 KDM1A

  1. |Ti|: number of tumor types whose genome-wide methylation levels are significantly associated with the mutation status of CDG i;
  2. N1: number of genes whose expression levels are dysregulated by MDG i in all |Ti| tumor types;
  3. N2: number of genes in list A that are dysregulated in all |Ti| tumor types;
  4. N3: number of genes in list B that are dysregulated in all |Ti| tumor types;
  5. Enrichment PvalueA, and PvalueB are calculated using hypergeometric distributions testing if genes in lists A and B are enriched among genome-wide differentially expressed target genes;
  6. aGenes in list B that are dysregulated in all |Ti| tumor types;
  7. bGenes in list B that are differentially methylated in all |Ti| tumor types.